Back to Report Store Home

Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity

  • Published: Aug-2013
  • Report Code: GBIHC302MR
  • Report Format: pdf

Description

List of Tables

List of Tables

Table 1: BMI Classifications

Table 2: Key Components of Pathways Thought to be Related to Obesity

Table 3: Treatment Options Dependent on BMI

Table 4: Obesity Therapeutics, Leading Brand Names of Phentermine

Table 5: Efficacy Results* for Qsymia at 52 Weeks

Table 6: Changes in Key Safety Parameters in Patients Treated with Qsymia

Table 7: Sales Data for Xenical ($m), 2008–2011

Table 8: Efficacy Results for Orlistat as an Initial and Maintenance Therapy

Table 9: Safety Results of Orlistat

Table 10: Efficacy Results for Belviq

Table 11: Placebo-adjusted Safety Results for Belviq

Table 12: Obesity Therapeutics Market, Global, Common Molecular Targets in the Obesity Pipeline

Table 13: Obesity Therapeutics Market, Global, Average Clinical Trial Size for the Most Common Modes of

Action Amongst Pipeline Drugs, 2006–2013

Table 14: Obesity Therapeutics Market, Global, Average Clinical Trial Duration for the Main Modes of

Action Amongst Pipeline Drugs, 2013

Table 15: Contrave, Phase III Clinical Trial Results

Table 16: Contrave, Efficacy Results, Phase III Clinical Trial

Table 17: Cametor, Efficacy Results of a Phase II Clinical Trial

Table 18: Cametor, Safety and Efficacy Results, Phase III Clinical Trial

Table 19: Victoza, Clinical Trial Results, Phase III Clinical Trial, 2009

Table 20: Victoza, Clinical Trial Results, Phase III Clinical Trial, 2009

Table 21: Victoza ,Safety and Efficacy Results, Phase III Clinical Trial, 2009

Table 22: Obesity Therapeutics Market, Europe, Current Prevalence Rate of the Population Which is

Obese or Overweight, 2012–2019

Table 23: Obesity Therapeutics Market: Global, Developmental Pipeline, Discovery Phase

Table 24: Obesity Therapeutics Market: Global, Developmental Pipeline, Preclinical Phase

Table 25: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase I

Table 26: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase II

Table 27: Obesity Therapeutics Market: Global, Developmental Pipeline, Phase III

Table 28: Obesity Pharmacotherapy Market: Global, Developmental Pipeline, Pre-Registration

Table 29: Obesity Therapeutics Market, Global, Market Forecasts, 2012–2019

Table 30: Obesity Therapeutics Market, US, Market Forecasts, 2012–2019

Table 31: Obesity Therapeutics Market, UK, Market Forecasts, 2012–2019

Table 32: Obesity Therapeutics Market, France, Market Forecasts, 2012–2019

Table 33: Obesity Therapeutics Market, Germany, Market Forecasts, 2012–2019

Table 34: Obesity Therapeutics Market, Italy, Market Forecasts, 2012–2019

Table 35: Obesity Therapeutics Market, Spain, Market Forecasts, 2012–2019

Table 36: Obesity Therapeutics Market, Japan, Market Forecasts, 2012–2019

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3500
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7000
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$10500
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards